These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 38627181)

  • 1. Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting.
    Raje NS; Cohen AD; Patel KK; van de Donk NWCJ; Richter J; San-Miguel J
    Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):350-357. PubMed ID: 38627181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific Antibodies in the Treatment of Multiple Myeloma.
    Zhou X; Xiao X; Kortuem KM; Einsele H
    Hematol Oncol Clin North Am; 2024 Apr; 38(2):361-381. PubMed ID: 38199897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma.
    Tacchetti P; Talarico M; Barbato S; Pantani L; Mancuso K; Rizzello I; Zamagni E; Cavo M
    Expert Rev Anticancer Ther; 2024 Jun; 24(6):379-395. PubMed ID: 38798125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond.
    Su CT; Ye JC
    J Hematol Oncol; 2021 Jul; 14(1):115. PubMed ID: 34301270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta-Analysis.
    Soltantabar P; Sharma S; Wang D; Lon HK; Czibere A; Hickmann A; Elmeliegy M
    Clin Pharmacol Ther; 2024 Jun; 115(6):1258-1268. PubMed ID: 38459622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update.
    Lakshman A; Kumar SK
    Am J Hematol; 2022 Jan; 97(1):99-118. PubMed ID: 34661922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell exhaustion in multiple myeloma.
    Żyłka K; Kubicki T; Gil L; Dytfeld D
    Expert Rev Hematol; 2024 Jul; 17(7):295-312. PubMed ID: 38919090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Charting the Course: Sequencing Immunotherapy for Multiple Myeloma.
    Mohan M; Van Oekelen O; Akhtar OS; Cohen A; Parekh S
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432204. PubMed ID: 38875506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?
    Martino M; Gamberi B; Antonioli E; Aquino S; Della Pepa R; Malerba L; Mangiacavalli S; Pezzatti S; Bringhen S; Zamagni E
    Expert Rev Hematol; 2024 Jul; 17(7):375-390. PubMed ID: 38770902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation.
    Hammons L; Haider S; Portuguese AJ; Banerjee R; Szabo A; Pasquini M; Chhabra S; Radhakrishnan S; Mohan M; Narra R; Dong J; Janz S; Shah NN; Hamadani M; D'Souza A; Hari P; Dhakal B
    Br J Haematol; 2024 Mar; 204(3):887-891. PubMed ID: 38054558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific antibodies for multiple myeloma: past, present and future.
    Ochi T; Konishi T; Takenaka K
    Int J Hematol; 2024 Jul; 120(1):23-33. PubMed ID: 38613724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management.
    Markouli M; Ullah F; Unlu S; Omar N; Lopetegui-Lia N; Duco M; Anwer F; Raza S; Dima D
    Curr Oncol; 2023 Jul; 30(7):6330-6352. PubMed ID: 37504327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel treatment strategies for hematological malignancies in the immunotherapy era.
    Imai Y
    Int J Hematol; 2024 Jul; 120(1):3-5. PubMed ID: 38861242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in multiple myeloma.
    Asensi Cantó P; Arnao Herraiz M; de la Rubia Comos J
    Med Clin (Barc); 2024 May; 162(10):485-493. PubMed ID: 38218655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating Immune Therapies for the Treatment of Multiple Myeloma.
    Mikkilineni L; Sidana S
    J Natl Compr Canc Netw; 2023 Dec; 21(12):1303-1311. PubMed ID: 38081142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future.
    Holstein SA; Grant SJ; Wildes TM
    J Clin Oncol; 2023 Sep; 41(27):4416-4429. PubMed ID: 37471687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
    Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
    J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future.
    Sunder-Plassmann V; Aksoy O; Lind J; Pecherstorfer M; Vallet S; Podar K
    Expert Opin Pharmacother; 2022 Aug; 23(12):1425-1444. PubMed ID: 35829636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.